阅读说明：本技术 C5a拮抗剂和ANCA相关性血管炎的剂量和疗效 (Dosage and therapeutic efficacy of C5a antagonists and ANCA-associated vasculitis ) 是由 邓军 P·贝克 J·希尔森 于 2019-06-06 设计创作，主要内容包括：本发明提供了治疗有此需要的人体中ANCA相关性血管炎的方法,该方法包括对人施用治疗有效量的阿伐可泮或其药学上可接受的盐,如此,在治疗后,该人的血浆补体因子Bb、C3a或C5a水平没有明显变化。(The present invention provides a method of treating ANCA-associated vasculitis in a human in need thereof, the method comprising administering a therapeutically effective amount of alvarepam or a pharmaceutically acceptable salt thereof to the human such that the plasma complement factor Bb, C3a, or C5a levels of the human are not significantly altered following treatment.)